News Room

Alzheimer's Disease

ABC Radio Jon Faine Program features Prana IMAGINE trial for Alzheimer’s disease

Melbourne – 22 August, 2012: Prana Biotechnology (NASDAQ:PRAN; ASX:PBT) today advised that Professor Michael Woodward, the National Study Coordinator for the Company’s Alzheimer’s disease IMAGINE trial, will be interviewed by ABC Radio commentator Jon Faine.

Prof. Woodward has been invited on to the program to discuss the IMAGINE trial. The interview will take place on ABC 774 Melbourne at 9.35am (Australian EST) Thursday 23rd August.

The IMAGINE trial, with 12 months of treatment, aims to establish PBT2 as a safe and effective treatment for Alzheimer’s disease. People aged 55 plus with mild Alzheimer’s disease are participating in the trial. The company has announced that this trial is progressing well with 100% of sites approved and actively recruiting. Already 40% of patients are in dosing with PBT2 and importantly no serious adverse events have been reported.

Currently, all available treatments for Alzheimer’s disease provide some degree of symptomatic relief; however, none change the course of the disease, or the eventual decline in a patient’s cognition and health. An extensive body of research suggests that PBT2 could do just that; disrupt the progression of Alzheimer’s disease and potentially stop the onset of the disease. Notably, this study has huge relevance for people who are experiencing the first stages of memory loss.

Prof. Woodward is one of the world’s leading experts in neurodegenerative disease and geriatrician.

To register your interest in the trial please call 1800 837 683.